163 related articles for article (PubMed ID: 33099695)
1. Statistical Considerations in Assessing In Vivo Adhesion with Transdermal and Topical Delivery Systems for New Drug Applications.
Wang C; Strasinger C; Shen M; Tsong Y
AAPS J; 2020 Oct; 22(6):137. PubMed ID: 33099695
[TBL] [Abstract][Full Text] [Related]
2. Statistical considerations and impact of the FDA draft guidance for assessing adhesion with transdermal delivery systems and topical patches for ANDAs.
Sun W; Grosser S; Kim C; Raney SG
J Biopharm Stat; 2019; 29(5):952-970. PubMed ID: 31495266
[TBL] [Abstract][Full Text] [Related]
3. Critical attributes of transdermal drug delivery system (TDDS)--a generic product development review.
Ruby PK; Pathak SM; Aggarwal D
Drug Dev Ind Pharm; 2014 Nov; 40(11):1421-8. PubMed ID: 24467407
[TBL] [Abstract][Full Text] [Related]
4. Use of Artificial Intelligence to Improve the Calculation of Percent Adhesion for Transdermal and Topical Delivery Systems.
Wang C; Strasinger C; Weng YT; Zhao X
J Med Syst; 2023 Dec; 48(1):4. PubMed ID: 38105364
[TBL] [Abstract][Full Text] [Related]
5. On the characterization of medicated plasters containing NSAIDs according to novel indications of USP and EMA: adhesive property and in vitro skin permeation studies.
Cilurzo F; Gennari CG; Selmin F; Franzé S; Musazzi UM; Minghetti P
Drug Dev Ind Pharm; 2015 Feb; 41(2):183-9. PubMed ID: 24164486
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Heat Effects on Transdermal Nicotine Delivery In Vitro and In Silico Using Heat-Enhanced Transport Model Analysis.
La Count TD; Zhang Q; Murawsky M; Hao J; Ghosh P; Dave K; Raney SG; Talattof A; Kasting GB; Li SK
AAPS J; 2020 Jun; 22(4):82. PubMed ID: 32488395
[TBL] [Abstract][Full Text] [Related]
7. Generic patches containing fentanyl: In vitro equivalence and abuse deterrent evaluation according to EMA and FDA guidelines.
Padula C; Pescina S; Nicoli S; Santi P
Int J Pharm; 2018 Feb; 537(1-2):57-63. PubMed ID: 29253583
[TBL] [Abstract][Full Text] [Related]
8. Generic drug device combination products: Regulatory and scientific considerations.
Choi SH; Wang Y; Conti DS; Raney SG; Delvadia R; Leboeuf AA; Witzmann K
Int J Pharm; 2018 Jun; 544(2):443-454. PubMed ID: 29170118
[TBL] [Abstract][Full Text] [Related]
9. Adhesive properties: a critical issue in transdermal patch development.
Cilurzo F; Gennari CG; Minghetti P
Expert Opin Drug Deliv; 2012 Jan; 9(1):33-45. PubMed ID: 22171789
[TBL] [Abstract][Full Text] [Related]
10. Influence of residual solvents on the physical properties of transdermal drug delivery systems.
Mazumder S; Shakleya D; Mattson S; Ashraf M; Faustino P; Pavurala N
Int J Pharm; 2020 Oct; 588():119713. PubMed ID: 32755689
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
[TBL] [Abstract][Full Text] [Related]
12. Recent advances on self modified patch for (trans) dermal drug delivery.
Pandey S; Patil A
Recent Pat Drug Deliv Formul; 2015; 9(1):88-94. PubMed ID: 24981287
[TBL] [Abstract][Full Text] [Related]
13. Fabrication, Physicochemical Characterization, and Performance Evaluation of Biodegradable Polymeric Microneedle Patch System for Enhanced Transcutaneous Flux of High Molecular Weight Therapeutics.
Shah V; Choudhury BK
AAPS PharmSciTech; 2017 Nov; 18(8):2936-2948. PubMed ID: 28432615
[TBL] [Abstract][Full Text] [Related]
14. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute.
Wokovich AM; Prodduturi S; Doub WH; Hussain AS; Buhse LF
Eur J Pharm Biopharm; 2006 Aug; 64(1):1-8. PubMed ID: 16797171
[TBL] [Abstract][Full Text] [Related]
15. Drug recrystallization in drug-in-adhesive transdermal delivery system: A case study of deteriorating the mechanical and rheological characteristics of testosterone TDS.
Mohamed LA; Kamal N; Elfakhri KH; Willett D; Wokovich A; Strasinger C; Cruz CN; Raney SG; Ashraf M; Zidan AS
Int J Pharm; 2020 Mar; 578():119132. PubMed ID: 32057892
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic delivery systems: a new approach to evaluate physical properties of transdermal delivery systems (TDS).
Ehrlich A; Henkel-Ernst J; Schaefer A; Assmussen B; Lücker PW
Methods Find Exp Clin Pharmacol; 1999; 21(1):69-71. PubMed ID: 10222451
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of in vitro/in vivo correlations for three fentanyl transdermal delivery systems using in vitro skin permeation testing and human pharmacokinetic studies under the influence of transient heat application.
Shin SH; Yu M; Hammell DC; Ghosh P; Raney SG; Hassan HE; Stinchcomb AL
J Control Release; 2022 Feb; 342():134-147. PubMed ID: 34838928
[TBL] [Abstract][Full Text] [Related]
18. Formulation and in vitro/in vivo evaluation of levodopa transdermal delivery systems.
Lee KE; Choi YJ; Oh BR; Chun IK; Gwak HS
Int J Pharm; 2013 Nov; 456(2):432-6. PubMed ID: 24008082
[TBL] [Abstract][Full Text] [Related]
19. Sumatriptan transdermal system can be correctly assembled and applied during migraine attacks.
Meadows KP; Pierce M; O'Neill C; Foster S; Jennings C
Headache; 2014 May; 54(5):850-60. PubMed ID: 24708392
[TBL] [Abstract][Full Text] [Related]
20. Transdermal delivery of alprazolam from a monolithic patch: formulation based on in vitro characterization.
Soler LI; Boix A; Lauroba J; Colom H; Domenech J
Drug Dev Ind Pharm; 2012 Oct; 38(10):1171-8. PubMed ID: 22204649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
